Up to 8 Years* of Patient Exposure From Phase 1 Trials Through Ongoing Open-Label Extension Study1-4

The Largest Number of Patients With RMS Studied in Pivotal
Head-to-Head Trials With an Active Comparator (N=2659)2,3a
SUNBEAM and RADIANCE study designs SUNBEAM and RADIANCE study designs
  • Annualized Relapse Rate
  • GdE Lesions
  • New/Enlarging T2 Lesions
  • Confirmed Disability Progression
Chart outlining DAYBREAK study structure Chart outlining DAYBREAK study structure
  • Long-Term Safety
  • Annualized Relapse Rate
  • GdE Lesions
  • New/Enlarging T2 Lesions

The patient population evaluated in this analysis included those who received ZEPOSIA 0.92 mg (n=881) and completed the randomized Phase 1, 2, or 3 trials.4 Endpoints were analyzed descriptively in the DAYBREAK study5

a2659 patients include all 3 arms of the study: the 0.92 mg dose of ZEPOSIA, the 0.46-mg dose of ZEPOSIA (not approved for maintenance dose), and the 30-μg dose of Avonex.2,3
bDAYBREAK is an ongoing open-label extension (OLE) trial that enrolled participants from multiple randomized phase 1 to 3 studies, including SUNBEAM and RADIANCE, and is presented as an interim analysis with a data cutoff of February 2, 2021.
cAt data cutoff, mean (range) continuous ozanimod 0.92 mg exposure in DAYBREAK was 47.6 (0.43-62.7) months.6
*From first patient randomized (October 18, 2012) through the DAYBREAK data cutoff (February 2, 2021), mean (range) continuous ozanimod 0.92 mg exposure was 67.4 (6.01-98.8) months.7
RMS=relapsing multiple sclerosis.
Key Inclusion Criteria1-3
  • Ages 18 to 55
  • EDSS score of 0.0 to 5.0
  • Experienced ≥1 relapse within the previous year
    OR 1 relapse within prior 2 years with ≥1 GdEbr
    lesion in prior year
Key Exclusion Criteria1-3
  • Primary progressive MS
  • Specific cardiac conditions (eg, recent MI/stroke,
    prolonged QTcF interval)
  • Resting heart rate <55 bpm at screening
  • T1DM or uncontrolled T2DM with hemoglobin A1C >9%
    (SUNBEAM) OR >7% (RADIANCE), or patients with
    diabetes with significant comorbidities
Baseline Characteristicsd
Characteristics (Mean Or %) SUNBEAM RADIANCE
Age (years) 35.4 35.6
Race, white 99.8% 98%
Sex, female 65% 68%
Time since MS symptom onset (years) 6.9 6.6
EDSS score (median) 2.5 2.5
Previously treated with MS therapiese 31% 29%
Number of relapses in prior year 1.3 1.3
≥1 T1 GdE lesion 48% 43%
Number of T1 GdE lesions 1.8 1.7
dIncludes 0.92 mg dose of ZEPOSIA and the 30-g dose of Avonex. The 0.46-mg maintenance dose of ZEPOSIA (not approved for maintenance dose) is not included.1
eIncludes those previously treated with non-steroid therapy for MS.1
A1C=glycated hemoglobin; BPM=beats per minute; EDSS=Expanded Disability Status Scale; MI=myocardial infarction; MS=multiple sclerosis; QTcF=prolonged Fridericia-corrected QT; T1DM=type 1 diabetes mellitus; T2DM=type 2 diabetes mellitus.
Get your patients
started on ZEPOSIA
Enroll your patients in ZEPOSIA 360 Support
and help them get started on treatment.
Helpful instructions to guide you through the process of getting your patients started on ZEPOSIA.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.